ZM-H1505R Placebo

OTHER3 trials

Sponsors

Shanghai Zhimeng Biopharma, Inc.

Conditions

Chronic Hepatitis BHealthy VolunteersHepatitis B, Chronic

Phase 1

A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R

CompletedNCT05470829

Shanghai Zhimeng Biopharma, Inc.Healthy Volunteers, Hepatitis B, Chronic

Start: 2021-05-27End: 2021-11-17Updated: 2022-07-22

Phase 2

A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB

Shanghai Zhimeng Biopharma, Inc.Hepatitis B, Chronic

Start: 2022-11-11End: 2024-12-30Target: 90Updated: 2023-05-08

Phase 3

A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB

Not yet recruitingNCT07095855

Shanghai Zhimeng Biopharma, Inc.Chronic Hepatitis B

Start: 2025-08-31End: 2030-01-31Target: 1300Updated: 2025-08-03

Related Papers

Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

BMC Medicine2023-03-1617 citations